Works matching DE "CANAGLIFLOZIN"

Results: 693
    1
    2
    3
    4
    5
    6

    Biocomputational Prediction Approach Targeting FimH by Natural SGLT2 Inhibitors: A Possible Way to Overcome the Uropathogenic Effect of SGLT2 Inhibitor Drugs.

    Published in:
    Molecules, 2021, v. 26, n. 3, p. 582, doi. 10.3390/molecules26030582
    By:
    • Mashraqi, Mutaib M.;
    • Chaturvedi, Navaneet;
    • Alam, Qamre;
    • Alshamrani, Saleh;
    • Bahnass, Mosa M.;
    • Ahmad, Khurshid;
    • Alqosaibi, Amany I.;
    • Alnamshan, Mashael M.;
    • Ahmad, Syed Sayeed;
    • Beg, Mirza Masroor Ali;
    • Mishra, Abha;
    • Shaikh, Sibhghatulla;
    • Rizvi, Syed Mohd Danish;
    • Tutone, Marco;
    • Almerico, Anna Maria
    Publication type:
    Article
    7
    8
    9
    10
    11
    12
    13
    14
    15
    16
    17
    18
    19
    20
    21
    22
    23
    24
    25

    real-world study on SGLT2 inhibitors and diabetic kidney disease progression.

    Published in:
    Clinical Kidney Journal, 2022, v. 15, n. 7, p. 1403, doi. 10.1093/ckj/sfac044
    By:
    • Liu, Allen Yan Lun;
    • Low, Serena;
    • Yeoh, Ester;
    • Lim, Eng Kuang;
    • Renaud, Claude Jeffrey;
    • Teoh, Selene Tse Yen;
    • Tan, Grace Feng Ling;
    • Chai, Chung Cheen;
    • Liu, Bo;
    • Subramaniam, Tavintharan;
    • Sum, Chee Fang;
    • Lim, Su Chi
    Publication type:
    Article
    26
    27

    Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation and Study of Diabetic Nephropathy with Atrasentan: what was learned about the treatment of diabetic kidney disease with canagliflozin and atrasentan?

    Published in:
    Clinical Kidney Journal, 2019, v. 12, n. 3, p. 313, doi. 10.1093/ckj/sfz070
    By:
    • Fernandez-Fernandez, Beatriz;
    • Fernandez-Prado, Raul;
    • Górriz, Jose Luis;
    • Martinez-Castelao, Alberto;
    • Navarro-González, Juan F;
    • Porrini, Esteban;
    • Soler, María José;
    • Ortiz, Alberto
    Publication type:
    Article
    28
    29
    30
    31
    32
    33

    Possible involvement of normalized Pin1 expression level and AMPK activation in the molecular mechanisms underlying renal protective effects of SGLT2 inhibitors in mice.

    Published in:
    Diabetology & Metabolic Syndrome, 2019, v. 11, n. 1, p. N.PAG, doi. 10.1186/s13098-019-0454-6
    By:
    • Inoue, Masa-Ki;
    • Matsunaga, Yasuka;
    • Nakatsu, Yusuke;
    • Yamamotoya, Takeshi;
    • Ueda, Koji;
    • Kushiyama, Akifumi;
    • Sakoda, Hideyuki;
    • Fujishiro, Midori;
    • Ono, Hiraku;
    • Iwashita, Misaki;
    • Sano, Tomomi;
    • Nishimura, Fusanori;
    • Morii, Kenichi;
    • Sasaki, Kensuke;
    • Masaki, Takao;
    • Asano, Tomoichiro
    Publication type:
    Article
    34

    Canagliflozin reduces epicardial fat in patients with type 2 diabetes mellitus.

    Published in:
    Diabetology & Metabolic Syndrome, 2017, v. 9, p. 1, doi. 10.1186/s13098-017-0275-4
    By:
    • Shusuke Yagi;
    • Yukina Hirata;
    • Takayuki Ise;
    • Kenya Kusunose;
    • Hirotsugu Yamada;
    • Daiju Fukuda;
    • Salim, Hotimah Masdan;
    • Gulinu Maimaituxun;
    • Susumu Nishio;
    • Yuriko Takagawa;
    • Saori Hama;
    • Tomomi Matsuura;
    • Koji Yamaguchi;
    • Takeshi Tobiume;
    • Takeshi Soeki;
    • Tetsuzo Wakatsuki;
    • Ken-ichi Aihara;
    • Masashi Akaike;
    • Michio Shimabukuro;
    • Masataka Sata
    Publication type:
    Article
    35

    Investigation of the Effect of Canagliflozin on the Disposition Index, a Marker of Pancreatic Beta Cell Function, in Patients with Type 2 Diabetes.

    Published in:
    Diabetes, Metabolic Syndrome & Obesity: Targets & Therapy, 2020, v. 13, p. 4457, doi. 10.2147/DMSO.S273396
    By:
    • Takahara, Mitsuyoshi;
    • Shiraiwa, Toshihiko;
    • Matsuoka, Taka-aki;
    • Yamamoto, Kaoru;
    • Maeno, Yoshifumi;
    • Shiraiwa, Yuka;
    • Yoshida, Yoko;
    • Katakami, Naoto;
    • Iijima, Hiroaki;
    • Katsumata, Hideyuki;
    • Arakawa, Kenji;
    • Hashimoto, Toshio;
    • Shimomura, Iichiro
    Publication type:
    Article
    36
    37
    38

    Empagliflozin in type 1 diabetes.

    Published in:
    Diabetes, Metabolic Syndrome & Obesity: Targets & Therapy, 2019, v. 12, p. 1555, doi. 10.2147/DMSO.S194688
    By:
    • Mathieu, Chantal;
    • Mooter, Laura Van Den;
    • Eeckhout, Bert
    Publication type:
    Article
    39
    40
    41
    42
    43
    44
    45
    46
    47
    48

    Anti-ageing effects of FDA-approved medicines: a focused review.

    Published in:
    Journal of Basic & Clinical Physiology & Pharmacology, 2023, v. 34, n. 3, p. 277, doi. 10.1515/jbcpp-2022-0242
    By:
    • Thanapairoje, Koranit;
    • Junsiritrakhoon, Supanut;
    • Wichaiyo, Surasak;
    • Osman, Mohd Azuraidi;
    • Supharattanasitthi, Wasu
    Publication type:
    Article
    49

    Lower prevalence of elevated liver stiffness measurements in people with type 2 diabetes taking sodium-glucose co-transporter 2 inhibitors or glucagon-like peptide-1 receptor agonists.

    Published in:
    Annals of Hepatology: Official Journal of the Mexican Association of Hepatology, 2023, v. 28, n. 6, p. 1, doi. 10.1016/j.aohep.2023.101142
    By:
    • Gracen, Lucy;
    • Muthukumara, Withma;
    • Aikebuse, Melanie;
    • Russell, Anthony;
    • O’Beirne, James;
    • Irvine, Katharine M.;
    • Williams, Suzanne;
    • Purii, Gaurav;
    • Valery, Patricia C.;
    • Hayward, Kelly L.;
    • Powell, Elizabeth E.
    Publication type:
    Article
    50